Cancer Biological Therapy Market

Cancer Biological Therapy Market: Global Industry Analysis and Opportunity Assessment 2016-2026

  • Ongoing
  • August 2020
  • REP-GB-2044
  • PDF PPT EXCEL
Cancer Biological Therapy Market
  • SELECT LICENSE TYPE :

  • US$5,000
  • US$7,500
  • US$10,000

This Cancer Biological Therapy market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Cancer Biological Therapy market.

Biological cancer therapies use the body’s immune system, either directly or indirectly, to fight cancer or to lessen the side effects that may be caused by some cancer treatments. It is also called biotherapy or biological response modifiers. Interferons and monoclonal antibodies are among the most promising biological approaches to cancer treatment. Biological therapy works by stimulating, boosting, restoring or acting like the body’s immune system response against cancer cells. Cancer is a leading cause of death worldwide. Factors that contribute to geographic differences in cancer occurrence include the prevalence of risk factors, the availability and use of diagnostic tests, variations in the age structure of the population, and the availability and quality of treatment. According to WHO, approximately 14 million new cases and 8.2 million cancer related deaths in 2012. Tobacco use is the most important risk factor for cancer causing around 20% of global cancer deaths and around 70% of global lung cancer deaths.

Cancer Biological Therapy Market: Drivers and Restraints

Market Growth Analysis

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

COVID -19 : Impact Analysis

Request the coronavirus impact analysis across industries and markets

Request Covid -19 Impact
/p>

Cancer Biological Therapy Market: Segmentation

The global Cancer Biological Therapymarket is classified on the basis of Product type, distribution channels and regional presence.

Cancer Biological Therapy Market: Overview

Cancer Biological Therapy Market: Regional Overview

Geographically, the market is dominated by North America, followed by Europe, Asia Pacific. Growth in the North American segment is primarily driven by presence of large number of cancer biological drug and vaccine manufacturers, increasing disposable income, affordable cancer treatment facility and growing number of health insurance coverage for life-threatening diseases. According to National Cancer Institute (NCI) an estimated 16, 85,210 new cases will be diagnosed in 2016, in the US. Europe is the second largest market .Asia pacific is expected to grow at a highest rate due to increasing prevalence of cancer patient, better healthcare facilities and growing number of insurance coverage. Japan contributes largest share in cancer treatment market in Asia Pacific due to high prevalence of cancer in Japanese population.

Cancer Biological Therapy Market: Key Players

Some of the major players operating in the market for Cancer Biological Therapy Market are F. Hoffmann-La Roche AG, Novartis International AG, Merck & Co., Inc., Amgen Inc., GlaxoSmithKline Plc, Bristol-Myers Squibb, Eli Lilly, Spectrum Pharmaceuticals, Inc., Seattle Genetics, Inc., Celgene Corporation and others

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Unique Requirements? Customize this Report

  • Customize by Region, Country, Application, Product, & other segments
  • Integrate our Insights with your Existing Data
  • Determine the scope of the study to suit your requirements

Let FMI Help You!

  • Gain Insights on Key Cancer Biological Therapy Market Impacting Forces
  • Know the Winning Strategies of Market Leaders
  • Get Deep-Dive Analysis on Each Segment
  • Identify the Sources that will Drive Top-Line Revenue

The factors such as growing prevalence of cancer, continuous patent expiry of cancer drugs, rising impact of biosimilars and increasing demand of biological and targeted drug therapies will drive the overall cancer biological therapy market. According to WHO, the number of new cancer cases is projected to rise 70% in the coming two decades, mainly due to increased use of tobacco and alcohol consumption. However, the threat of failure in treatment, the high cost of drug development, the adverse effects of cancer drug therapy, particularly chemotherapy and stricter government regulations will hinders the overall cancer biological therapy market growth globally.

Cancer Biological Therapy Market: Segmentation

Segmentation based on product type:

  • Vaccines
  • Cancer growth blockers
    • Tyrosine kinase inhibitors
    • Proteasome inhibitors
    • mTOR inhibitors
  • Monoclonal antibodies
    • Naked monoclonal antibodies
    • Conjugated monoclonal antibodies
    • Bispecific monoclonal antibodies
  • Cytokines
    • Interferons
    • Interleukins
  • Blood cell growth factors
    • Lenograstim
    • Filgrastim
  • Gene therapy

Segmentation based on distribution channels:

  • Hospital pharmacies
  • Retail pharmacies
  • Mail order pharmacies

The immune system protects a person from infection and disease. The Biological therapies are used to lessen the spread and lower the risk of recurrence for some cancers, slow the growth, control symptoms of cancer, deliver radioactive substances or chemotherapy drugs directly to a tumour lessen and some of the side effects from cancer treatments. Immune system recognize antigens on the surface of viruses, bacteria, other germs and cancer cells. Antigens mark these cells as being different (foreign) so the immune system can find them. The immune system reacts to these antigens and destroys the cells they are attached to. According to Globocan, in economically developed countries, 58% of all newly diagnosed cancer cases occur at 65 years of age and older, compared with 40% in developing countries. When countries are grouped according to income, cancer is the second leading cause of death in high-income countries and the third leading cause of death in low- and middle-income countries. Among females, the most common cancer sites were either breast or cervical cancer, with the exceptions of South Korea (thyroid), Mongolia and Laos (liver) and China and North Korea (lung).

Cancer Biological Therapy Market: Regional Overview

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
  • Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
  • Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint.
Frequently Asked Questions

Why choose FMI?
  • With a global presence and a trusted partner to several Fortune 500 firms, FMI covers 1 billion+ data points to build a diversified portfolio for market benchmarking
  • Market Reports researched and peer reviewed by industry experts from across the globe
  • We follow a multi-dimensional method of analysis monitoring a three-layer data validation process
  • In addition to demand-side market assessment, our data triangulation methodology involves supply-side research
  • Primary research includes mandatory field interviews with stakeholders involved
  • Customizing reports according to client specification is also our forte
  • The current and future market size, covering each aspect and nuanced trends across key national and geographic markets
  • An overview of the market report, providing an imperative visual of the varied market subdivisions and overall forecast statistics in terms of value and volume
  • Extensive database and key dynamics elevating the market with varied verticals associated
  • Underlying Cancer Biological Therapy Market forces that are compelling consumers or businesses to purchase the product
  • How novel technologies and consumer-centric innovations will create new value-adding opportunities for companies active in the Cancer Biological Therapy Market
  • What will be environment and regulatory impacts on the market over the next decade
  • Investment Feasibility Matrix - It shows returns on investment, level of competition, success rate of investment, and potential risks associated with the market. The analysis shows that the competition is high in the established market, while the returns for short-term investment are also taken into consideration
  • Relative Maturity Mapping – The relative maturity is measured according to three growth phases (growth, maturity, decline)
  • Relative PLC (Product Life Cycle) – Analysis of the emergence of prominent players and competitive test prices which are driving factors behind every market. (expected market behavior, observed market behavior, expected market performance, observed market performance)
Get in touch
Harish Tiwari

Harish Tiwari

Global Head - Business Development

Akshay Godge

Akshay Godge

Client Partner - Global Business Development

Our Clients


Request Sample Request customization Request Methodology